AZN — ASTRAZENECA PLC
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 901832 ·
United Kingdom
Last close
$161.47
Market Cap
$250.42B
52W High
$210.52
52W Low
$153.41
ADV30
3,065,699
Next earnings
2026-10-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 15,384,000,000 | 12,861,000,000 | 3,164,000,000 | 2,507,000,000 | 115,833,000,000 | 4,893,000,000 | 65,463,000,000 |
| Mar 2026 | 15,288,000,000 | 12,610,000,000 | 4,246,000,000 | 3,080,000,000 | 114,015,000,000 | 7,560,000,000 | 66,631,000,000 |
| Dec 2025 | 15,503,000,000 | 12,385,000,000 | 2,978,000,000 | 2,326,000,000 | 114,074,000,000 | 5,711,000,000 | 65,355,000,000 |
| Sep 2025 | 15,191,000,000 | 12,390,000,000 | 3,583,000,000 | 2,533,000,000 | 114,456,000,000 | 8,143,000,000 | 68,485,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$13,700,000,000
Investing CF
$-8,151,000,000
Financing CF
$-7,680,000,000
CapEx
$-7,656,000,000
Dividends Paid
$-4,902,000,000
Buybacks
—
EPS Diluted TTM
$6.64
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$12,592,000,000
Inventory
$6,932,000,000
Receivables
—
ST Investments
$75,000,000
EBIT TTM
$14,332,000,000
Pretax Income TTM
$12,586,000,000
Interest Exp TTM
$1,746,000,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$61,366,001,664
EBITDA
$19,904,000,000
Free Cash Flow
$4,905,375,232
Enterprise Value
$275,880,673,280
Total Cash
$4,968,000,000
Total Debt
$32,349,999,104
Shares Out
1,550,895,914
Trailing EPS
$6.68
Book Value
$32.43
ROE
22.0%
ROA
8.0%
Div Yield
2.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 58,739,000,000 | 13,327,000,000 | 10,225,000,000 | 114,074,000,000 | 65,355,000,000 | 48,667,000,000 | 14,575,000,000 |
| Dec 2024 | 54,073,000,000 | 10,251,000,000 | 7,035,000,000 | 104,035,000,000 | 63,164,000,000 | 40,786,000,000 | 11,861,000,000 |
| Dec 2023 | 45,811,000,000 | 8,722,000,000 | 5,955,000,000 | 101,119,000,000 | 61,953,000,000 | 39,143,000,000 | 10,345,000,000 |
| Dec 2022 | 44,351,000,000 | 4,512,000,000 | 3,288,000,000 | 96,483,000,000 | 59,425,000,000 | 37,037,000,000 | 9,808,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$11.36
Max Pain — expiry 2027-01-15
max pain strike: $85.00 · spot: $161.47 · call oi: 2,855 · put oi: 3,512
Expected Move to 2027-01-15:
±$20.73
(12.84%) —
implied range
$140.74 –
$182.20
· ATM straddle on $160.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NVSEF | NOVARTIS AG | $267.87B | $140.93 | — |
| NVS | NOVARTIS AG | $270.98B | $142.57 | — |
| MRK | Merck & Co., Inc. | $358.50B | $145.31 | — |
| ABT | ABBOTT LABORATORIES | $171.01B | $98.83 | — |
| PFE | PFIZER INC | $162.55B | $28.52 | — |
News headlines (Yahoo Finance, 1h cache)
700,000 Seniors Have Started GLP-1s Through Medicare. Now AstraZeneca Just Moved a Once-Daily Pill Into Phase 3
2026-09-30 20:43 · Yahoo
Drug Repurposing Market - Global Strategic Business Report: Forecasts Growth to $37.3Billion by 2030, Profiling AbbVie, AstraZeneca, Pfizer, Novartis & Johnson & Johnson
2026-09-30 13:40 · Yahoo
AstraZeneca (LSE:AZN) Wins FDA Priority Review For IMFINZI In Bladder Cancer
2026-09-30 12:12 · Yahoo
Is AstraZeneca (LSE:AZN) Undervalued Following Its New Lung Cancer FDA Filing?
2026-09-30 10:09 · Yahoo
Astrazeneca (AZN) Registers a Bigger Fall Than the Market: Important Facts to Note
2026-09-29 21:15 · Yahoo
AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, Merck
2026-09-29 20:55 · Yahoo
A $2 Billion Reason Why AstraZeneca Stock Is Down Today
2026-09-29 19:39 · Yahoo
AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says
2026-09-29 19:03 · Yahoo
AstraZeneca Stock Slips as $2 Billion Summit Stake Deepens Oncology
2026-09-29 17:17 · Yahoo
Summit Stock Jumps 17% on $2 Billion AstraZeneca Investment
2026-09-29 16:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.